Compare ATCX & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCX | GBIO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8M | 36.3M |
| IPO Year | N/A | 2020 |
| Metric | ATCX | GBIO |
|---|---|---|
| Price | $8.18 | $5.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | 35.6K | ★ 71.9K |
| Earning Date | 03-16-2023 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $367,030.00 | ★ $15,270,000.00 |
| Revenue This Year | $109,631.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.80 | $3.00 |
| 52 Week High | $47.16 | $10.40 |
| Indicator | ATCX | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.58 |
| Support Level | N/A | $5.31 |
| Resistance Level | N/A | $5.70 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 76.09 |
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.